TIDMHVO

RNS Number : 6926D

hVIVO plc

28 April 2017

For immediate release 2.00pm: 28 April 2017

HVIVO PLC

("hVIVO" or the "Company")

2016 Annual Report and Financial Statements

hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, is pleased to announce that its Annual Report and Financial Statements for the year ended 31 December 2016 is being posted to shareholders today. It will be available on the Company's website (http://hvivo.com/investors/financial-reports/) from 4.30 pm today.

For further information please contact:

 
     hVIVO plc                                +44 207 756 1300 
     Kym Denny (Chief Executive 
      Officer) 
     Graham Yeatman (Chief Financial 
      & Business Officer) 
 
                                              +44 203 021 3933 
                                               / 
     Media Enquiries                           +44 7854 979 420 
     Colin Paterson (Director of 
      Marketing, Communication and 
      Public Relations) 
 
     Numis Securities Limited                  +44 207 260 1000 
     Michael Meade / Freddie Barnfield 
      (Nominated Adviser) 
     James Black / Michael Burke 
      (Corporate Broking) 
 
     FTI Consulting 
     Simon Conway / Victoria Foster 
      Mitchell (UK)                           +44 203 727 1000 
     John Capodanno / Evan Smith 
      (US)                                    +1 212 850 5705

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSOKFDNCBKKAQB

(END) Dow Jones Newswires

April 28, 2017 09:00 ET (13:00 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hvivo Charts.
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hvivo Charts.